Shares of Biogen Inc. BIIB shed 3.41% to $150.03 Friday, on what proved to be an all-around mixed trading session for the ...

In a rare move, the U.S. agency behind Medicare is warning Medicare Advantage providers they can’t have blanket policies that ...

Integrated Wealth Concepts LLC reduced its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 61.3% during the third ...

The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen ...

Biogen Inc. closed $112.97 below its 52-week high ($268.30), which the company achieved on January 3rd.

CMS has reportedly directed Medicare Advantage plan providers to cover Biogen's drug Qalsody for ALS following reports it was ...

It is hard to get excited after looking at Biogen's (NASDAQ:BIIB) recent performance, when its stock has declined ...

Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...

Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by equities research analysts at Jefferies Financial Group from a “buy” ...

BofA reinstated coverage of Biogen (BIIB) with a Neutral rating and $178 price target Biogen is “a cheaper name,” mostly because Leqembi for ...

Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains ...

US biotech major Biogen today announced the appointment of Tim Power as vice president, head of investor relations, effective immediately. Mr. Power will report to Michael McDonnell, executive VP and ...